Back to Studies

IMPAACT 2034

Phase I Study of the Pharmacokinetics, Safety, and Acceptability of Pretomanid in Children with Rifampicin-Resistant Tuberculosis

Summary

What is IMPAACT 2034?

IMPAACT 2034 is a Phase I, multi-site, open-label, pharmacokinetic (PK), safety, tolerability, and acceptability study of a single-dose of pretomanid (Pa) in infants, children, and adolescents less than 18 years of age living with or without HIV and confirmed or probable rifampicin-resistant tuberculosis. Participants will be given a single-dose of pretomanid, added to their TB treatment regimen, with intensive PK sampling. After receiving the single dose of Pa, participants will be followed for two weeks for safety.

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...